GPR35 as a Novel Therapeutic Target.

Area of Science:

• Pharmacology and drug discovery
• Molecular and cellular biology
• Receptor pharmacology

Background:

• G protein-coupled receptors (GPCRs) are crucial drug targets, yet many remain poorly understood.
• GPR35, a GPCR discovered over a decade ago, has been an "orphan" receptor with undefined endogenous ligands.
• Recent research has identified novel ligands for GPR35, sparking interest in its therapeutic potential.

Purpose of the Study:

• To explore the characterization of the GPR35 receptor.
• To investigate the role of GPR35 in various diseases.
• To identify novel agonist and antagonist ligands for GPR35 to determine its physiological relevance.

Main Methods:

• Review of recent publications on GPR35.
• Analysis of identified endogenous and synthetic ligands.
• Assessment of species-selective properties of ligands.
• Evaluation of GPR35's role in disease models (in vitro and in vivo).

Main Results:

• Novel potent ligands (endogenous and synthetic) for GPR35 have been identified.
• Evidence suggests GPR35 involvement in diseases such as diabetes, hypertension, and asthma.
• Identified ligands exhibit significant species-selective properties, posing drug development challenges.

Conclusions:

• GPR35 is emerging as a promising therapeutic target for various diseases.
• Further research is needed to fully elucidate GPR35's physiological roles and overcome drug development hurdles.
• Identifying novel ligands is key to translating GPR35 research from in vitro and animal models to human applications.